Analyst Expectations for Y-mAbs Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Y-mAbs Therapeutics (NASDAQ:YMAB) has received various analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, 1 indifferent, and 1 somewhat bearish. The average price target is $16.0, compared to the current price of $6.24, implying an upside. This average price target has increased by 48.15% over the past month.
July 25, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Y-mAbs Therapeutics has received mixed analyst ratings, with an average price target of $16.0, implying a potential upside.
The average price target given by analysts is significantly higher than the current price of Y-mAbs Therapeutics, indicating a potential upside. This, along with the fact that the average price target has increased by 48.15% over the past month, suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100